Over the last several years, our laboratory has spent considerable time developing antibody–drug conjugates that consist of hydrophobic chemotherapeutic agents, including PTX and SN-38, that are packaged within albumin nanoparticles [39,40] and coated with tumor-directed human IgG1 antibodies, creating a nano-immune conjugate (NIC). Here, ALB is linked to neoplasm.